Infinity Pharmaceuticals, Inc. (INFI)
| Market Cap | 237.71M |
| Revenue (ttm) | 1.59M |
| Net Income (ttm) | -41.28M |
| Shares Out | 60.51M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $2.69 |
| Previous Close | $2.76 |
| Change ($) | -0.07 |
| Change (%) | -2.54% |
| Day's Open | 2.78 |
| Day's Range | 2.33 - 2.78 |
| Day's Volume | 2,881,294 |
| 52-Week Range | 0.60 - 5.98 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company, today announced that management will present at the H.C. Wainwright Gl...
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Infinity Pharmaceuticals is my pick for Stock of the Year. And Shopify is my selection for Stock of the Decade.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially firs...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a potentially firs...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, an oral, immuno-on...
The company reported results from a clinical study.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncol...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today presented data from MARIO-275 (MAcrophage Reprogramming in Immune Oncology)...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncol...
Infinity Pharmaceuticals (NASDAQ: INFI) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Pharmaceuticals is a clinical-stage biopharmace...
With the trading day about halfway over, the broad markets were trading sideways into the weekend.
Does Infinity Pharmaceuticals (INFI) have what it takes to be a top stock pick for momentum investors? Let's find out.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will participate in a Fireside Chat with Andrew D'Silva of B. Riley Securities on Wednesday, January 20, 2021 a...
Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting data from MARIO-275 on the first day of the American Society of Clinical Oncology (ASCO) 202...
Infinity (INFI) provides an update on Eganelisib in patients with metastatic urothelial cancer.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this m...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today provided an update on MARIO-275, the Company's randomized, placebo controlled Phase 2 study evaluating th...
Sorrento Therapeutics (NASDAQ: SRNE) shares are trading higher on Wednesday after the company announced it has received CLIA Licensure from the State of California that permits testing of clin...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that data from the front-line triple negative breast cancer (TNBC) cohort from the ongoing MARI...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoi...
Recent results pleased analysts. The company's relationship with various Big Pharma companies will be key to future revenues and to the stock price.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in ...
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q3 2020 Results - Earnings Call Transcript
Infinity (INFI) delivered earnings and revenue surprises of -6.67% and 130.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its third quarter 2020 financial results and provided an update on the Company, including its t...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the presentation of data from the melanoma and squamous cell carcinoma of the head and neck (SC...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class immuno-oncology product candida...
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for eganeli...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q2 2020 Results - Earnings Call Transcript
Infinity (INFI) delivered earnings and revenue surprises of 20.00% and 80.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc.
Infinity (INFI) reported earnings 30 days ago. What's next for the stock?
Infinity (INFI) saw a big move last session, as its shares jumped nearly 5% on the day, amid huge volumes.
Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q1 2020 Results - Earnings Call Transcript
Infinity (INFI) delivered earnings and revenue surprises of -111.11% and 74.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Infinity (INFI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Infinity (INFI) reported earnings 30 days ago. What's next for the stock?
The FDA bestows a Fast Track designation on Infinity's (INFI) IPI-549 in combination with Opdivo for treating advanced urothelial cancer. Stock rise.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) shares are trading higher on Wednesday, after the company announced the FDA has granted fast track designation for IPI-549 in combination with niv...
Infinity (INFI) posts a wider-than-expected loss for the fourth quarter of 2019.
Infinity Pharmaceuticals, Inc. (INFI) CEO Adelene Perkins on Q4 2019 Results - Earnings Call Transcript
Infinity (INFI) delivered earnings and revenue surprises of -5.26% and 8.83%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
About INFI
Infinity Pharmaceuticals, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, I... [Read more...]
| Industry Biotechnology | |
| CEO Adelene Perkins | Employees 25 |
| Stock Exchange NASDAQ | Ticker Symbol INFI |
Financial Performance
In 2019, INFI's revenue was $3.05 million, a decrease of -86.23% compared to the previous year's $22.15 million. Losses were -$47.06 million, 318.2% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for INFI stock is "Buy." The 12-month stock price forecast is 7.60, which is an increase of 182.53% from the latest price.